Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1851 results
June 2018
-
Story Discovery
Women in Science: Kristen Harrington-Smith
Kristen Harrington-Smith discusses her work as Vice President and Head of CAR-T US at Novartis Oncology.
-
Press release
Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis
26 abstracts on Cosentyx® (secukinumab) in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) will be presented at the Annual European Congress of Rheumatology (EULAR 2018)[1]… -
Story Discovery
Open resources at Novartis help drive innovation
With external help from Novartis, an Argentinian researcher was able to begin his search for a new medicine for tuberculosis.
-
Press release
Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs
Patients reported prolonged maintenance of global health status[1](overall health) Longer time to deterioration (TTD) seen across multiple clinically relevant symptom categories including… -
Press release
Novartis Schullabor empfängt hunderttausendsten Besucher
Basel, 6. Juni, 2018 - Mit dem heutigen Besuch einer Schulklasse des Gymnasiums am Münsterplatz in Basel hat das Novartis Schullabor die magische Zahl von über 100'000 Besucherinnen und Besuchern… -
Press release
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line… -
Press release
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
ENESTop and ENESTfreedom data evaluate Treatment-free Remission (TFR) rates at 144 weeks among eligible Ph+ CML-CP patients who stopped Tasigna® Findings further support durability and… -
Ad hoc release
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
Basel, June 1, 2018 - Novartis AG ("Novartis") today announced the completion of the divestment to GlaxoSmithKline PLC ("GSK") of its 36.5 percent stake in a consumer healthcare joint venture (JV)… -
Press release
Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology Positive CHMP opinion… -
Ad hoc release
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
If approved, Aimovig®(erenumab) is expected to be the first and only available therapy designed specifically for migraine prevention in the EU Positive opinion based on robust data package…
May 2018
-
Press release
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (… -
Story Discovery
Immuno-oncology researchers seek to build smart drug combos
Novartis has launched a comprehensive research program to help find the right combinations of therapies for the right patients.